Case Report

Effective salvage of recurrent craniopharyngioma with fractionated stereotactic radiotherapy

Laura Burgess\textsuperscript{a,b,}\textsuperscript{*}, Santanu Chakraborty\textsuperscript{c}, Shawn Malone\textsuperscript{a,b}

\textsuperscript{a} Department of Radiology, Division of Radiation Oncology, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H8L6, Canada
\textsuperscript{b} The Ottawa Hospital Research Institute, Ottawa, Ontario K1H8L6, Canada
\textsuperscript{c} Department of Radiology, University of Ottawa, Ottawa, Ontario, K1H8L6, Canada

\textbf{ARTICLE INFO}

\textbf{Article history:}
Received 1 May 2020
Revised 29 June 2020
Accepted 4 July 2020

\textbf{Keywords:}
Craniopharyngioma
Stereotactic radiotherapy
Image-guided radiotherapy
Neuroradiology

\textbf{ABSTRACT}

Craniopharyngiomas can invade surrounding structures, including the optic chiasm and hypothalamus. In such cases, subtotal resection is often preferred to limit perioperative morbidity and mortality; however, subtotal resection is associated with high rates of recurrence. Recurrent craniopharyngioma is typically treated with another subtotal resection and adjuvant radiotherapy. We present a case of a patient found to have a large craniopharyngioma compressing the optic chiasm, hypothalamus and left cavernous sinus. She underwent surgical debulking but developed recurrence shortly thereafter. Subsequently, she underwent a second debulking surgery, followed by fractionated stereotactic radiotherapy (SRT). Results show that she exhibited an impressive response to SRT with further tumor shrinkage, while remaining clinically well. This case demonstrates the efficacy of SRT in salvage of recurrent craniopharyngioma.

© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

\textbf{Introduction}

Craniopharyngiomas are rare embryonic tumors that arise from remnants of Rathke’s pouch. Despite a low histological grade, craniopharyngiomas can cause significant morbidity as a result of growth into the surrounding region, with the most common location being the sellar/parasellar region [1]. Common clinical manifestations include symptoms of elevated intracranial pressure including headache, nausea and vomiting, visual impairment and endocrine deficits secondary to hypothalamic-pituitary axis involvement. These endocrine deficits frequently lead to a reduced growth rate, significant weight gain and diabetes insipidus [2,3].

Given such morbidity, effective treatment is warranted. For craniopharyngiomas that do not involve the optic chiasm or hypothalamus, gross total resection is the preferred treatment [4,5]. Controversy remains about the optimal treatment when the optic apparatus and/or hypothalamus are involved [5,6]. Subtotal resection tends to be preferred, to minimize morbidity and mortality, but is associated with high recurrence rates; with rates of progression as high as 70%-90% [7,8].
A 15-year-old girl was referred by her family physician to an endocrinologist for evaluation of primary amenorrhea. She was found to be prepubertal (Tanner stage 1) and had a significant growth delay. She had no signs or symptoms of increased intracranial pressure. She was growth hormone deficient and hypogonadal, and no evidence of central adrenal insufficiency, central hypothroidism or diabetes insipidus was present. She complained of impaired vision in her right eye and ophthalmologic assessment revealed bitemporal hemianopsia as well as decreased visual acuity in the right eye. A central etiology was suspected given her symptom complex. MRI brain (Fig. 1) revealed a large (38 mm × 42 mm × 46 mm; sizes at various time points included in Table 1) solid and cystic predominantly suprasellar mass lesion that was partially calcified. The optic chiasm, hypothalamus and left cavernous sinus were significantly compressed by the lesion. Additionally, there was no parenchymal invasion and no surrounding edema, and imaging findings were consistent with a craniopharyngioma.

She was sent for assessment by neurosurgery and underwent endoscopic transsphenoidal resection of the suprasellar mass lesion, with decompression of the optic chiasm, left cavernous sinus and hypothalamus. Pathology revealed World Health Organization grade 1 adamantinomatous craniopharyngioma. She developed panhypopituitarism postoperatively and was started on hydrocortisone, growth hormone, levothyroxine and estrogen. An early postoperative MRI brain (Fig. 2) revealed good debulking with maximal residual disease measuring 20 mm × 32 mm × 30 mm. In follow up, she felt well and noted improvement in her vision.

An MRI brain (Fig. 3) completed 4.5 months after debulking revealed significant recurrence of the cystic suprasellar lesion, now measuring 44 mm × 51 mm × 38 mm in size. There was mass effect from the tumor on the hypothalamus and right inferomedial temporal lobe. A repeat debulking surgery was recommended by neurosurgery. The patient was amid her academic year and wished to postpone her debulking until completion of the academic year. She remained clinically asymptomatic and so the decision was to proceed with her secondary surgery after completion of the school year.

A repeat MRI brain 2.5 months later demonstrated further interval tumor growth, now 44 mm × 52 mm × 45 mm. She remained asymptomatic, apart from significant weight gain. Eight months after her initial de-bulking surgery, she underwent a repeat endoscopic transsphenoidal resection of the suprasellar mass lesion. Pathology once again revealed World Health Organization grade 1 adamantinomatous craniopharyngioma, and an MRI brain 1 month postoperatively (Fig. 4) showed an interval decrease in size with the mass measuring 27 mm × 28 mm × 21 mm.

Given the rapid tumor regrowth following her first debulking surgery, she was referred to radiation oncology for

---

**Table 1 – The size of the craniopharyngioma at critical timepoints in the clinical course of this patient.**

| Timepoint                           | Size (AP, transverse, craniocaudal, in mm) |
|-------------------------------------|------------------------------------------|
| Preoperative/diagnosis              | 38 × 42 × 46                              |
| Postoperative, first debulking      | 20 × 32 × 30                              |
| Initial recurrence                  | 44 × 51 × 38                              |
| Before second debulking             | 44 × 52 × 45                              |
| Postoperative, second debulking, preradiotherapy | 27 × 28 × 21                             |
| Postradiotherapy                    | 3 × 27 × 18                               |

Consequently, subtotal resection is frequently followed by adjuvant radiotherapy, which reduces rates of progression by 75%-90% [7–9].

With this in mind, we present a case of recurrent craniopharyngioma that failed multiple surgical resections but demonstrates a significant response to fractionated stereotactic radiotherapy (SRT).
Fig. 2 – MR images on day 1 after first debulking surgery; (A) sagittal spin echo T1, (B) coronal turbo spin echo T2.

Fig. 3 – MR images 4.5 months after first debulking surgery, demonstrating rapid recurrence; (A) sagittal turbo spin echo T1, (B) coronal turbo spin echo T2.

Fig. 4 – MR images 1 month postoperatively from second debulking surgery, demonstrating preradiotherapy disease burden; (A) Sagittal turbo spin echo T1, (B) coronal turbo spin echo T2 MR images.
consideration of radiotherapy. She was offered fractionated SRT, given the proximity to the optic chiasm, with the goal of improving local control. Fractionation was deemed important to spare the optic pathway while delivering an adequate radiotherapy dose to control the tumor. She underwent SRT with 5000 cGy delivered in 25 fractions over 5 weeks. SRT involved a 2 arc VMAT plan on an Elekta Linear Accelerator. Daily cone beam imaging was used for image guidance. SRT was completed approximately 1 year from her first debulking surgery. She tolerated SRT well with no nausea, fatigue or visual changes.

Follow up imaging 9 months after completion of SRT (Fig. 5) demonstrated significant interval regression of the suprasellar mass with the fluid component shrinking to 3 mm × 27 mm × 18 mm. No significant mass effect was demonstrated. She remains clinically well in follow-up with no new neurologic symptoms or cognitive deficits, as well as on full hormone replacement and she no longer has a bitemporal hemianopsia.

**Discussion**

Despite being low-grade tumors, craniopharyngiomas can cause significant sequelae due to their proximity and tendency to invade the optic chiasm and hypothalamic-pituitary axes [9,10]. Its relatively benign histology lends well to the possibility of cure with resection, and hence, the first line treatment is surgical resection [4-6]. There remains significant debate with regards to optimal surgical management, with any involvement of the optic apparatus or hypothalamic-pituitary axes, whether gross total resection or subtotal resection offer the best approach [11-14].

Typically with such involvement, subtotal resection is preferred to gross total resection, as gross total resections can lead to significant hypothalamic injury [13,15,16]. However, this choice is associated with high rates of recurrence. The results of a multicenter prospective trial by Muller et al., demonstrated a 3-year overall survival of 97%, but an event-free survival of 46%, highlighting the high rates of recurrence in this population [8]. In patients who were able to have a complete resection, the 3-year event-free survival was 64%, but this decreased significantly to only 31% in those who had a subtotal resection. While subtotal resection remains the safer option with any involvement of the optic chiasm or hypothalamic-pituitary axes, this approach comes at the cost of significantly increased recurrence rates; with relative recurrence rates 80% higher following subtotal relative to gross total resection. This same prospective trial also found that the risk of progression or recurrence was 88% lower in patients who received adjuvant radiotherapy. This effectively highlights the potential benefit of adjuvant radiotherapy, but the recurrence rates still remain high in patients following subtotal resection combined with adjuvant radiotherapy.

At the time of her initial presentation, given the compression of the optic chiasm, hypothalamus and left cavernous sinus, the neurosurgeon in this case opted to proceed with the more conservative approach of subtotal resection. Unfortunately, the patient in this case was among most patients who undergo incomplete resection and developed progression of her disease, requiring further treatment. This may have been avoided with the use of adjuvant radiotherapy, but the use of radiotherapy is not without consequences and so the decision was to defer any such treatment.

It is important to note, though, that the management of recurrent craniopharyngioma remains a challenge. This is primarily due to scarring from previous surgery and potential radiotherapy as well as the eloquent location of the tumor near the optic chiasm. This results in a significantly reduced ability to achieve complete resection with a second surgery [1,4] and perioperative morbidity and mortality is also significantly higher. Therefore, radiotherapeutic options tend to be preferred, often preceded by a debulking surgery [4,17]. This is how the patient in our report was managed when she recurred following initial subtotal resection; with repeat debulking surgery followed by fractionated SRT.

Adjuvant radiotherapy is an effective means of treatment in patients with craniopharyngioma [18]. Several retrospective series have demonstrated excellent long-term control with adjuvant radiotherapy, reporting 5-year, 10-year and 20-year progression-free survival of 78%-95%, 56%-95% and 54%-66%, respectively [13,14,19-24]. Studies have also investigated the timing of adjuvant radiotherapy, whether it can wait until relapse, as was done in this case. No significant difference in

---

**Fig. 5** – MR images 9 months after adjuvant radiotherapy, demonstrating excellent response (A) sagittal rapid gradient echo T1, (B) coronal fluid-attenuated inverse recovery T2.

---
tumor control has been demonstrated between early radiotherapy and radiotherapy following relapse [17,25]. Accordingly, with the hopes of delaying side effects of radiotherapy, it is frequently delayed until relapse. The patient in our case report completed adjuvant radiotherapy 1 year after her initial surgery, having started radiotherapy 3 months postoperatively from her second debulking surgery. While common, this strategy may not be ideal. Retrospective data exists to suggest that neurocognitive outcomes may be improved with a single subtotal resection followed by adjuvant radiotherapy, rather than attempting complete resection or to wait for relapse and subsequent interventions [26]. This data remains quite limited, though, and further study is required.

Lastly, with advances in radiotherapeutic techniques, there are more radiotherapy options in the treatment of craniopharyngioma. These include stereotactic radiosurgery, fractionated SRT and proton beam radiotherapy. Proton therapy, where dose deposition increases with penetration up until a maximum (Bragg peak), after which no dose is deposited, offers conformal dose distributions, with reduced integral dose and critical tissue sparing [27]. Stereotactic radiosurgery involves delivery of single (or few) fractions of radiotherapy with limited margins. Often, patients with craniopharyngioma treated with this modality have small (<3 cm) tumors ≥ 3 mm away from critical structures and strict dose constraints to the optic nerve, chiasm and brain stem [28,29]. Fractionated SRT also offers sparing of normal tissues while having advantages of fractionation [30], particularly helpful in larger tumors and tumors near critical structures, minimizing toxicities from radiotherapy [31,32]. Data in patients treated with proton therapy, stereotactic radiosurgery and SRT are still somewhat limited, but there have been promising results with good local control [28,31–34]. The patient in this case was treated with fractionated SRT, due to the proximity of the tumor to the optic chiasm. This allows for the benefits of conformity that stereotactic techniques offer, while taking advantage of radiobiological effects of fractionation to spare the optic chiasm.

Herein, we reviewed a case of a patient with craniopharyngioma treated with an initial debulking surgery who had rapid regrowth of her craniopharyngioma. Recurrence is common and is often treated with a second debulking surgery followed by adjuvant radiotherapy. She was treated in this manner and demonstrated an impressive response following completion of fractionated SRT.

**Funding sources**

None.

**Competing interest**

Shawn Malone has honoraria from the following: Astella, Janssen, Sanofi, Bayer, Abbvie, AstraZeneca, Amgen.

Shawn Malone has travel grants from the following: Sanofi, TerSera.

**REFERENCES**

[1] Karavitaki N, Bruhani C, Warner JT, et al. Craniopharyngioma in children and adults: systematic analysis of 121 cases with long-term follow-up. Clin Endocrinol (Oxf) 2005;62(4):397–409. doi:10.1111/j.1365-2265.2005.02231.x.

[2] Caldarrelli M, Massimi L, Tamburrini G, Cappa M, Di Rocco C. Long-term results of the surgical treatment of craniopharyngioma: the experience at the Policlinico Gemelli, Catholic University, Rome. Child’s Nerv Syst 2005;21(8–9):747–57. doi:10.1007/s00381-005-1186-5.

[3] Mortini P, Gagliardi F, Boari N, Loss M. Surgical strategies and modern therapeutic options in the treatment of craniopharyngiomas. Crit Rev Oncol Hematol 2013;88(3):514–29. doi:10.1016/j.critrevonc.2013.07.013.

[4] Fahlibusch R, Honegger J, Paulus W, Huk W, Buchfelder M. Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 1999;90(2):237–50. doi:10.3171/jns.1999.90.2.0237.

[5] Puget S. Treatment strategies in childhood craniopharyngioma. Front Endocrinol (Lausanne) 2012;3(JUN):1–7. doi:10.3389/fendo.2012.00064.

[6] Buchfelder M, Schlaffer SM, Lin F, Kleindienst A. Surgery for craniopharyngioma. Pituitary 2013;16(1):18–25. doi:10.1007/s11102-012-0414-8.

[7] Becker G, Kortmann RD, Skalej M, Bamberg M. The role of radiotherapy in the treatment of craniopharyngioma - indications, results, side effects. Front Radiat Ther Oncol 1999;39:100–13.

[8] Müller HL, Gebhardt U, Schröder S, et al. Analyses of treatment variables for patients with childhood craniopharyngioma - results of the ulcerinter Prospective Trial KRAINIOPHARYNGEOM 2000 after three years of follow-up. Horm Res Paediatr 2010;73(3):175–80. doi:10.1159/000284358.

[9] Müller HL. Craniopharyngioma. Endocr Rev 2014;35(3):513–43. doi:10.1200/er.2013-1115.

[10] Karavitaki N, Cudlip S, Adams CB, Wass JAH. Craniopharyngiomas. Endocr Rev 2006;27(4):371–97. doi:10.1200/er.2006-0002.

[11] Elowe-Gruau E, Beltrand J, Brauner R, et al. Childhood craniopharyngioma: hypothalamus-sparing surgery decreases the risk of obesity. J Clin Endocrinol Metab 2012;98(6):2376–82. doi:10.1210/jc.2012-2392.

[12] Vinchon M, Welll J, Delestret I, Dhellemmes P. Craniopharyngioma and hypothalamic obesity in children. Child’s Nerv Syst 2009;25(3):347–52. doi:10.1007/s00381-008-0754-x.

[13] Hetelekidis S, Barnes PD, Tso ML, et al. 20-year experience in childhood craniopharyngioma. Int J Radiat Oncol Biol Phys 1993;27:189–95.

[14] Rajan B, Ashley S, Gorman C, et al. Craniopharyngioma - long-term results following limited surgery and radiotherapy. Radiother Oncol 1993;26(1):1–10. doi:10.1016/0167-8140(93)90019-5.

[15] Zuccaro G. Radical resection of craniopharyngioma. Child’s Nerv Syst 2005;21(8–9):679–90. doi:10.1007/s00381-005-1201-x.

[16] Puget S, Garnett M, Wray A, et al. Pediatric craniopharyngiomas: classification and treatment according to the degree of hypothalamic involvement. J Neurosurg 2007;106(1 SUPPL.):3–12. doi:10.3171/ped.2007.106.1.3.

[17] Gazi Yasargil M, Curric M, Kis M, Siegenthaler G, Teddy P, Roth P. Total removal of craniopharyngiomas. Approaches and long-term results in 144 patients. J Neurosurg 1990;73(1):3–11.

[18] Müller HL, Merchant TE, Puget S, Martinez-Barbera JP. New
outlook on the diagnosis, treatment and follow-up of childhood-onset craniopharyngioma. Nat Rev Endocrinol 2017;13(5):299–312. doi: 10.1038/nrendo.2016.217.

[19] Carmel PW, Antunes JL, Chang CH. Craniopharyngiomas in children. Neurosurgery 1982;11(3):382–9.

[20] Habrand JL, Ganry O, Couanet D, et al. The role of radiation therapy in the management of craniopharyngioma: a 25-year experience and review of the literature. Int J Radiat Oncol Biol Phys 1999;44(2):255–63. doi: 10.1016/S0360-3016(99)00030-9.

[21] Flickinger JC, Lunsford LD, Singer J, Cano ER, Deutsch M. Megavoltage external beam irradiation of craniopharyngiomas: analysis of tumor control and morbidity. Int J Radiat Biol Phys 1990;19(1):117–22.

[22] Mark RJ, Lutge WR, Shimizu KT, Tran LM, Seich MT, Parker RG. Craniopharyngioma: treatment in the CT and MR imaging era. Ther Radiol 1995;197:195–8.

[23] Varlotto JM, Flickinger JC, Kondziolka D, Lunsford LD, Deutsch M. External beam irradiation of craniopharyngiomas: long-term analysis of tumor control and morbidity. Int J Radiat Oncol Biol Phys 2002;54(2):492–9. doi: 10.1016/S0360-3016(02)02965-6.

[24] Pemberton LS, Dougal M, Magee B, Gattamaneni HR. Experience of external beam radiotherapy given adjuvantly or at relapse following surgery for craniopharyngioma. Radiother Oncol 2005;77(1):99–104. doi: 10.1016/j.radonc.2005.04.015.

[25] Regine WF, Mohiuddin M, Kramer S. Long-term results of pediatric and adult craniopharyngiomas treated with combined surgery and radiation. Radiother Oncol 1993;27(1):13–21. doi: 10.1016/0167-8140(93)90039-B.

[26] Merchant ThE, Kiehna EN, Sanford RA, et al. Craniopharyngioma: the St. Jude Children’s research hospital experience 1984 – 2001. J Radiat Oncol Biol Phys 2002;53(3):533–42.

[27] Boehling NS, Grosshans DR, Bluett JB, et al. Dosimetric comparison of three-dimensional conformal proton radiotherapy, intensity-modulated proton therapy, and intensity-modulated radiotherapy for treatment of pediatric craniopharyngiomas. Int J Radiat Oncol Biol Phys 2012;82(2):643–52. doi: 10.1016/j.ijrobp.2010.11.027.

[28] Kobayashi T, Kida Y, Mori Y, Hasegawa T. Long-term results of gamma knife surgery for the treatment of craniopharyngioma in 98 consecutive cases. J Neurosurg 2005;103(SUPPL. 6):482–8 PEDIAT. doi: 10.1016/j.ijrobp.2005.10.3.048.

[29] Chiu S-M, Lunsford LD, Niranjan A, Kondziolka D, Flickinger JC. Stereotactic radiosurgery of residual or recurrent craniopharyngioma, after surgery, with or without radiation therapy. Neuro Oncol 2004;3(3):159–66. doi: 10.1215/s152281760000491.

[30] Combs SE, Thilmann C, Huber PE, Hoess A, Debus J, Schulz-Ertner D. Achievement of long-term local control in patients with craniopharyngiomas using high precision stereotactic radiotherapy. Cancer 2007;109(11):2308–14. doi: 10.1002/cncr.22703.

[31] Schubert T, Trippel M, Tacke U, et al. Neurosurgical treatment strategies in childhood craniopharyngiomas: is less more? Child’s Nerv Syst 2009;25(11):1419–27. doi: 10.1007/s00381-009-0978-4.

[32] Schulz-Ertner D, Frank C, Herfarth KK, Rhein B, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy for craniopharyngiomas. Int J Radiat Oncol Biol Phys 2002;54(4):1114–20. doi: 10.1016/S0360-3016(02)03029-8.

[33] Winkfield KM, Tsai HK, Yao X, et al. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer 2011;56:1120–6.

[34] Fitzek MM, Linggood RM, Adams J, Munzenrider JE. Combined proton and photon irradiation for craniopharyngioma: long-term results of the early cohort of patients treated at Harvard Cyclotron Laboratory and Massachusetts General Hospital. Int J Radiat Oncol Biol Phys 2006;64(5):1348–54. doi: 10.1016/j.ijrobp.2005.09.034.